X

Earnings Summary: Everything you need to know about IDEXX’s Q4 2023 report

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a provider of pet healthcare innovation, on Monday reported higher revenues and net income for the fourth quarter of 2023.

  • Fourth-quarter revenues increased 9% annually to $901.6 million; organic revenue growth was 8%
  • Net income attributable to shareholders moved up to $194.52 million from $172.2 million a year earlier
  • On a per-share basis, fourth-quarter earnings rose to $2.32 per share from $2.05 per share in Q4 2022
  • For fiscal 2024, the management expects revenues to be in the range of $3.93 billion to $4.04 billion, reflecting a growth of 7.5-10.5%
  • Full-year organic revenue growth is expected to be between 7% and 10%
  • The management is looking for earnings of $10.84 per share to $11.33 per share for FY24, an increase of 8-13% as reported and on a comparable basis
Related Post